title: An open-label study of naltrexone in the treatment of kleptomania.
abstract: BACKGROUND
  The present study was designed to test the short-term efficacy and safety of naltrexone in the treatment of kleptomania.
  
  
  METHODS
  10 subjects (7 women, 3 men) who fulfilled DSM-IV criteria for kleptomania and were free from other Axis I diagnoses by the Structured Clinical Interview for DSM-IV screening participated in a 12-week naltrexone open-label trial. Kleptomania symptom change was assessed with the Clinical Global Impressions scale (both severity and improvement measures), Sheehan Disability Scale (SDS), Global Assessment of Functioning (GAF), and Kleptomania Symptom Assessment Scale. Side effects were monitored weekly, and liver function tests were administered every 2 weeks.
  
  
  RESULTS
  Naltrexone reduced urges to steal and stealing behavior. Subjects showed significant improvement (p < .005) over the 11-week treatment period in all measures compared with measures taken at baseline. Seven subjects (70.0%) were very much improved and 2 (20.0%) were much improved at study end. Subjects also reported overall significant improvement in social and occupational functioning as determined by both the GAF and the SDS (p < .000). Men responded to naltrexone as well as women. The mean naltrexone dose required for effective symptom control was 145 mg/day. Nausea was common during the first week of treatment. Five subjects (50.0%) reported previous trials of medication and cognitive-behavioral therapy without any effect on kleptomania symptoms.
  
  
  CONCLUSIONS
  The present findings provide evidence that naltrexone may be effective in the treatment of kleptomania. The present report is preliminary. Further studies are needed to confirm these findings.
authors: Department of Psychiatry, University of Minnesota Medical School, Minneapolis 55454-1495, USA. grant045@umn.edu
authors: Jon E
authors: JE
authors: Grant
authors: Suck Won
authors: SW
authors: Kim
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D015203:Reproducibility of Results; D012720:Severity of Illness Index; D012737:Sex Factors; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D009292:Narcotic Antagonists; D010919:Placebos; D009271:Naltrexone